For the quarter ended March 2025, Immunocore Holdings PLC Sponsored ADR (IMCR) reported revenue of $93.88 million, up 33.2% over the same period last year. EPS came in at $0.10, compared to -$0.49 in the year-ago quarter.The reported revenue represents a surprise of +7.84% over the Zacks Consensus Estimate of $87.06 million. With the consensus EPS estimate being -$0.35, the EPS surprise was +128.57%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how t ...

"We are thrilled to have achieved strong revenue performance in Q1, marked by year-over-year growth of 33%. This reflects our unwavering dedication to making KIMMTRAK accessible to patients who need it," said Bahija Jallal, Chief Executive Officer of Immunocore. "In R&D, we continue to be laser-focused on execution in our oncology franchise with three ongoing Phase 3 trials and a promising early pipeline. We are also excited to have presented the initial MAD data at CROI from our ongoing HIV trial, which, t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-39992 Immunocore Holdings plc (Exact name of registrant as specified in its charter) | England and Wales | Not A ...

Immunocore reports first quarter financial results and provides a business update KIMMTRAK (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable securities of ...

Shares of Immunocore Holdings PLC Sponsored ADR (IMCR) have gained 6.4% over the past four weeks to close the last trading session at $30.47, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $63.21 indicates a potential upside of 107.5%.The average comprises 14 short-term price targets ranging from a low of $24 to a high of $100, with a standard deviation of $23.20. While the low ...

Immunocore Holdings PLC Sponsored ADR (IMCR) shares ended the last trading session 6% higher at $30.43. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 3.6% loss over the past four weeks.Earlier this month, the company presented encouraging initial data from the multiple ascending dose portion of the phase I/II STRIVE study evaluating its functional cure candidate, IMC-M113V, for treating human immunodeficiency vir ...

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 IMC-M113V was well tolerated, with no dose-limiting toxicities Signals of dose-dependent reduction in active reservoir, and viral control after complete antiretroviral treatment interruption in some PLWH Enrollment in MAD portion of the trial continues with higher doses being evaluated (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 10 March 2025) Immunocore Ho ...

Core Insights - Immunocore Holdings is a biotech company focused on immunotherapy in oncology, gaining attention for its novel treatment approach to rare skin cancers approved in 2022 [1] Company Overview - Immunocore Holdings operates in the oncology space, specifically targeting immunotherapy solutions [1] Recent Developments - The company made a significant impact with the approval of a new treatment for rare skin cancers, marking a pivotal moment in its development [1]

Immunocore Holdings plc (NASDAQ:IMCR) Q4 2024 Earnings Conference Call February 26, 2024 8:00 AM ET Company Participants Clayton Robertson - Head, IR Bahija Jallal - CEO Travis Coy - CFO and Head, Corporate Development Ralph Torbay - Head, Commercial David Berman - Head, R&D Conference Call Participants Michael Yee - Jefferies Jessica Fye - JPMorgan Tyler Van Buren - TD Cowen Eric Schmidt - Cantor Fitzgerald Justin Zelin - BTIG Jonathan Chang - Leerink Partners Ethan Markowski - Needham & Company Peter Laws ...

KIMMTRAK Performance and Market Potential - KIMMTRAK Q1-Q3 2024 net sales reached $226M, with potential to help up to 6K patients per year in the US and Europe[11] - KIMMTRAK has been launched in 45 countries as of December 31, 2024, with Q1-Q3 2024 net revenue from these launches[13] - KIMMTRAK active in cutaneous melanoma (CM) with Phase 1/2 study showing durable disease control in patients who progressed on prior anti-PD1 therapy[15] - KIMMTRAK's dosing frequency in CM patients shows durable response regardless of time since last dose of anti-PD1 therapy[15] - KIMMTRAK (tebentafusp) is being evaluated in a Phase 3 trial for adjuvant uveal melanoma, targeting ~1,200 patients[47] - The company's preliminary, unaudited year-end cash position is $820M, with $226M in commercial revenues from KIMMTRAK[43] Clinical Trials and Pipeline Development - TEBE-AM Phase 3 trial in 2L+ cutaneous melanoma targets a market opportunity of up to 4,000 patients, with expected enrollment completion in 1H 2026[18][19] - ATOM Phase 3 trial for KIMMTRAK in adjuvant uveal melanoma shows 88% ctDNA reduction in 1st line treatment and 71% in 2nd+ line treatment[21] - HIV STRIVE Phase 1 trial for IMC-M113V has enrolled 15 people living with HIV (PLWH) as of June 2024, with biologically active dose reached and Phase 1 MAD data planned for 1Q 2025[30] - Immunocore's pipeline includes candidates across oncology, autoimmune diseases, and infectious diseases, with multiple Phase 1/2 and Phase 3 trials ongoing[6][7] - PRISM-MEL-301, a Phase 3 trial for first-line advanced cutaneous melanoma, is enrolling ~10,000 HLA-A02+ patients annually in the US and Europe[72] - The company is evaluating brenetafusp in combination with standard-of-care therapies for ovarian and NSCLC, with enrollment expected in 2025[54] - PRAME franchise expansion opportunities include HLE and A24 programs, with IND/Phase 1 trials planned[54] Therapeutic Potential and Innovation - Immunocore's TCR therapeutics can target >90% of the human proteome, offering a broad therapeutic potential[5] - Immunocore's vision for autoimmunity includes tissue-specific downmodulation of the immune system, aiming to suppress activation only in inflamed tissues[33] - IMC-S118AI for type 1 diabetes (T1D) is expected to submit CTN for Phase 1 trial by end of 2025, targeting 160,000 newly diagnosed T1D patients annually in the US and EU5[35] - IMC-U120AI is a non-HLA restricted bispecific candidate for dermatology, addressing a broader patient population beyond HLA-A02[43] - PRAME-A02-HLE targets 20,000 PIWIL+ CRC patients, expanding the addressable patient population[43] Brenetafusp Clinical Data - Brenetafusp monotherapy in cutaneous melanoma showed a median H-score of 215 for PRAME expression, with 89% of patients being PRAME positive[58] - Brenetafusp monotherapy demonstrated a durable disease control rate (DCR) of 58% in PRAME+ patients, with a median progression-free survival (mPFS) of 3.7 months[69] - Median age of patients in monotherapy group is 63 years (range 40-80) and in chemo combo group is 65 years (range 47-72)[75] - 51% of monotherapy patients had ECOG PS 0, compared to 25% in chemo combo group[75] - 94% of monotherapy patients were PRAME positive, while 81% in chemo combo group were PRAME positive[75][77] - Disease Control Rate (DCR) for monotherapy was 58% with a median Progression-Free Survival (mPFS) of 3.3 months[82] - 6-month Overall Survival (OS) rate for monotherapy was 73%[82] - Treatment-related adverse events (TRAE) occurred in 97% of monotherapy patients and 100% of chemo combo patients[78] - Grade 3/4 TRAE were reported in 19% of monotherapy patients and 50% of chemo combo patients[78] - Cytokine Release Syndrome (CRS) was observed in 57% of monotherapy patients and 75% of chemo combo patients[78] - ALT increased in 11% of monotherapy patients and 50% of chemo combo patients[78] - AST increased in 5% of monotherapy patients and 50% of chemo combo patients[78]